NRx Pharmaceuticals Inc. (NRXP), a clinical-stage biopharmaceutical company, is gearing up for key milestones this year as it advances its lead drug candidate NRX-100.
NRX-100 (ketamine) is an intravenous formulation of ketamine in development for the treatment of patients with severe depression and acute suicidal ideation.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com